Table 1 Baseline characteristics of female and male patients with T2D of the study population
| Â | All | Men | Women | p-value |
|---|---|---|---|---|
N (%) | 2083 | 1148 (55.1%) | 935 (44.9%) | Â |
Age (years) | 60.92 (± 0.29) | 60.29 (± 0.37) | 61.68 (± 0.44) | 0.009 |
BMI (kg/m²) | 29.19 (± 0.13) | 28.9 (± 0.16) | 29.55 (± 0.19) | 0.007 |
HbA1c (%) | 7.37* (± 0.03) | 7.26* (± 0.04) | 7.48 (± 0.04) | < 0.001 |
NT-proBNP (pg/ml) | 244.75 (± 8.88) | 248.29 (± 13.08) | 240.41 (± 11.54) | < 0.001 |
Creatinine (mg/dl) | 1.04 (± 0.01) | 1.12 (± 0.01) | 0.94 (± 0.01) | < 0.001 |
eGFR (ml/min) | 73.27 (± 0.1) | 76.78 (± 0.56) | 68.94 (± 0.57) | < 0.001 |
DM duration (years) | 13.64 (± 0.27) | 13.43 (± 0.37) | 13.89 (± 0.4) | 0.346 |
LDL (mg/dl) | 104.63 (± 0.78) | 103.84 (± 1.15) | 105.60 (± 1.02) | 0.029 |
Arterial Hypertension (%) | 1437 (69.0%) | 784 (65.2%) | 653 (69.8%) | 0.448 |
AF (%) | 52 (2.5%) | 32 (2,8%) | 20 (2.1%) | 0.340 |
CABG (%) | 74 (3.6%) | 63 (5.5%) | 11 (1.2%) | < 0.001 |
PCI (%) | 74 (3.6%) | 53 (4.6%) | 21 (2.2%) | 0.014 |
NYHA class |  |  |  | < 0.001 |
 NYHA I (%) | 1782 (85.5%) | 1015 (88.4%) | 767 (82.0%) |  |
 NYHA II (%) | 234 (11.2%) | 107 (9.3%) | 127 (13.6%) |  |
 NYHA III (%) | 63 (3.0%) | 26 (2.3%) | 37 (4.0%) |  |
 NYHA IV (%) | 4 (0.2%) | 0 | 4 (0.4%) |  |
RAS inhibitors (%) | 1212 (58.2%)** | 669 (58.3%) | 543 (58.1%) | 0.958 |
Beta-blocker (%) | 599*** (28.9%) | 329 (28.7%) | 270 (29.1%) | 0.847 |
Diuretics (%) | 695**** (33.4%) | 357 (31.1%) | 338 (36.3%) | 0.014 |
Aldosterone antagonist (%) | 65***** (3.1%) | 30 (2.6%) | 35 (3.8%) | 0.220 |
Insulin (%) | 1138 (54.6%) | 640 (55.8%) | 498 (53.3%) | 0.257 |
Statin (%) | 918 (44.1%) | 496 (43.2%) | 422 (45.1%) | 0.656 |
PAD (%) | 189 (9.1%) | 94 (8.2%) | 95 (10.2%) | 0.119 |
CVD (%) | 111 (0.5%) | 74 (6.4%) | 37 (4.0%) | 0.012 |